<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980561</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00089933</org_study_id>
    <nct_id>NCT03980561</nct_id>
  </id_info>
  <brief_title>UH3 Varenicline for Cannabis Use Disorder</brief_title>
  <official_title>Varenicline for the Treatment of DSM 5 Cannabis Use Disorder in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Marijuana is the most commonly used illicit drug. There is high demand for effective
      interventions for cannabis use disorder, yet few specific treatments for have been developed.
      This study will evaluate the efficacy of varenicline for reducing marijuana use in people who
      use marijuana frequently.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of varenicline, compared with placebo, for reducing cannabis use: total number of use sessions at each weekly visit</measure>
    <time_frame>Treatment phase Weeks 6-12</time_frame>
    <description>Cannabis use reduction as measured by daily substance use logs and examined as the total number of use sessions at each weekly visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of varenicline, compared with placebo, when used for cannabis use disorder: frequency of treatment-emergent AEs</measure>
    <time_frame>12 weeks (across the active treatment period)</time_frame>
    <description>Comparing the frequency of treatment-emergent AEs between treatment groups. Of particular interest will be AEs leading to medication discontinuation and the occurrence of treatment-related serious AEs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Active medication</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive medication</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must meet DSM-5 criteria for cannabis use disorder and use cannabis at least 3 days
             per week in the last 30 days.

          -  Express interest in receiving treatment for cannabis use disorder and reducing use.

          -  Must be at least 18 years of age.

          -  If female and of childbearing potential, must agree to use acceptable methods of birth
             control for the duration of the trial.

          -  Must consent to random assignment, and be willing to commit to medication ingestion.

          -  Must be able to read and provide informed consent.

          -  Must have body weight &gt;110lbs (50kg) and have BMI between 18 and 35kg/m2

          -  Must function at an intellectual level and have knowledge of the English language to
             sufficiently allow for accurate completion of assessments.

        Exclusion Criteria:

          -  Women who are pregnant, nursing, or plan to become pregnant during the course of the
             study.

          -  Individuals with severe renal impairment (creatinine clearance less than 30 mL per
             minute).

          -  Lifetime history of DSM-5 Bipolar I or II Disorder, Schizophrenia or other psychotic
             disorder. Stably treated MDD, Dysthymia, GAD, Social Phobia, and Specific Phobia
             diagnoses are acceptable (i.e. same dose of medication has been prescribed for at
             least 2 months prior to screening and no changes in current medication expected during
             course of the trial).

          -  Suicidal ideation or behavior within the past 6 months. Subjects who are believed to
             be at suicidal or homicidal risk (answers 'yes' on questions 4 or 5 of C-SSRS) will be
             referred for assessment by a qualified mental health professional.

          -  Concomitant use of psychotropic medications, with the exception of stable doses
             (defined as no dosing adjustments in the past two months) of non-MAO-I
             antidepressants, non-benzodiazepine anxiolytics, and ADHD medications.

          -  Current use of medications prescribed for mania or psychosis.

          -  Current use of buproprion or nortryptiline.

          -  Moderate or severe non-cannabis substance use disorders within the past 60 days with
             the exception of tobacco use disorder.

          -  Individuals taking an investigational agent within the last 30 days before baseline
             visit.

          -  Individuals with clinically significant medical disorders or lab abnormalities.

          -  Any individual at screening with SGOT (AST) or SGPT (ALT) greater than 3 times the
             upper limit of normal and/or total bilirubin greater than two times the upper limit of
             normal.

          -  Individuals with clinically significant cardiovascular disease in the past 6 months
             (e.g., myocardial infarction, CABG, PTCA, severe or unstable angina, serious
             arrhythmia, or any clinically significant ECG conduction abnormality.

          -  Individuals with clinically significant cerebrovascular disease in the past 6 months
             such as TIA, CVA, or stroke.

          -  Hypersensitivity to varenicline.

          -  Individuals who have participated in the clinical trial of any investigative compound
             within the last 60 days

          -  Individuals who are on probation or under a mandate to obtain treatment.

          -  Individuals with plans to initiate or change frequency of attendance at self-help
             meetings (e.g. AA, NA).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee McRae-Clark, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Wagner, MA</last_name>
    <phone>843-792-0484</phone>
    <email>wagne@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Nunn, MS</last_name>
    <phone>843-792-0476</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Wagner, MA</last_name>
      <phone>843-792-0484</phone>
      <email>wagne@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patrick Cato</last_name>
      <phone>843-792-4215</phone>
      <email>catop@musc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Behavioral Health Services of Pickens County</name>
      <address>
        <city>Pickens</city>
        <state>South Carolina</state>
        <zip>29671</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Chapman, BS, LCAC</last_name>
      <phone>864-898-5800</phone>
      <email>echapman@bhspickens.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>marijuana</keyword>
  <keyword>substance use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

